White Papers

MIPS 2020: Providers Can Earn Credit by Participating in COVID-19 Clinical Trials

On April 20, 2020, CMS announced that, as part of its effort to prompt clinicians who take part in the Merit-based Incentive Payment System (MIPS) to contribute to research and evidence initiatives for the COVID-19 pandemic, new Improvement Activity COVID-19 Clinical Trials has been created.

The new improvement activity requires clinicians to attest that they participate in a COVID-19 clinical trial utilizing a drug or biological product and report their findings through a clinical data repository or clinical data registry for the duration of the study.

According to the press release, there is flexibility in the type of clinical trial in which clinicians participate, “which could include the traditional double-blind placebo-controlled trial to an adaptive or pragmatic design that flexes to workflow and clinical practice.”

The COVID-19 Clinical Trials activity designation in the MIPS program is IA_ERP_3 and has been assigned a weight of High for category scoring purposes.

APS will provide additional details as they become available from CMS.

Access the press release at:

For more information on the COVID-19 clinical trials, go to the U.S. National Library of Medicine website at: https://clinicaltrials.gov/ct2/results?cond=COVID-19

Recent White Papers

Update: UHC Delays New Compliance Requirement for Laboratory Test Registration Protocol
November 24th, 2020
Update - 2021 Pricing Change for High Throughput COVID-19 Testing
November 24th, 2020
UHC Prior Authorization & Site of Service Update for Colonoscopy
November 24th, 2020
Be Aware of These Changes in 2021 If You Bill Office/Other Outpatient E&M Codes
October 29th, 2020


In working through the wide variety of billing arrangements, APS found payments that we had been missing.

Los Angeles, CA

Are you ready to start seeing increased revenues? APS’ expertise and commitment to service can get you there.
Begin your partnership with APS Medical Billing.
Contact Us